ENTERO THERAPEUTICS (ENTO) Enters $100 Billion+ AI and Data Center Market with Acquisition of GRID AI
Rhea-AI Summary
Entero Therapeutics (NASDAQ:ENTO) has announced a transformative acquisition of GRID AI Corp, positioning itself in the rapidly growing AI energy-infrastructure market. GRID AI's platform utilizes AI and machine learning to manage distributed energy resources and balance power supply and demand in real-time.
The deal structure gives GRID AI shareholders 82.5% ownership of ENTO's fully diluted common stock, while existing ENTO shareholders retain 17.5%. GRID AI's technology addresses the surging power demands from AI data centers, with Goldman Sachs projecting global data-center power demand to increase ~50% by 2027 and up to 165% by 2030 versus 2023 levels.
The acquisition leverages over $50 million invested in GRID AI since 2019, targeting a market expected to see AI infrastructure investments exceeding $2.8 trillion by 2029.
Positive
- Strategic entry into AI energy infrastructure market with projected $2.8 trillion investment by 2029
- Scalable SaaS revenue model targeting utilities, retailers, and hyperscalers
- Access to established technology with $50 million prior investment since 2019
- Positioned to capitalize on projected 165% growth in data-center power demand by 2030
Negative
- Significant dilution for existing ENTO shareholders, retaining only 17.5% ownership
- Major shift from therapeutic focus requires complete business transformation
- Loss of control with GRID AI shareholders gaining right to appoint 5 of 7 directors
- Requires NASDAQ approval and shareholder vote for change of control
News Market Reaction
On the day this news was published, ENTO declined 14.20%, reflecting a significant negative market reaction. Argus tracked a peak move of +31.5% during that session. Argus tracked a trough of -34.3% from its starting point during tracking. Our momentum scanner triggered 24 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $1M from the company's valuation, bringing the market cap to $8M at that time. Trading volume was very high at 4.3x the daily average, suggesting heavy selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Transaction positions ENTO in the high-growth AI energy-infrastructure market, amid a surge of multi-billion-dollar hyperscaler spending on data centers, and rapid growth in behind-the-meter energy storage solutions
BOCA RATON, FL / ACCESS Newswire / October 1, 2025 / Entero Therapeutics, Inc. (NASDAQ:ENTO) ("ENTO" or the "Company") today announced it has acquired
Over
"This transaction is transformative for ENTO," said Jason Sawyer, Interim Chief Executive Officer of ENTO. "By combining GRID AI's grid-edge intelligence with our public-company platform, we intend to scale solutions that help utilities and hyperscalers meet unprecedented AI-driven power demand while improving grid reliability for consumers and enterprises alike."
Hyperscalers are redefining power demand; AI build-out fuels multi-trillion-dollar capex
AI workloads are driving a step-function increase in electricity consumption from data centers. Goldman Sachs Research projects global data-center power demand to rise ~
Recent marquee commitments underscore the scale: for example, a
Where GRID AI fits: balancing the grid between consumers and corporations
Governments and network operators face an urgent challenge: managing increasingly peaky, localized loads from AI data centers while integrating variable renewables and protecting consumer reliability. GRID AI's DLS™ platform directly addresses this challenge by unlocking flexible demand from millions of devices, enabling automated demand shaping, price-responsive load, and DER aggregation that can defer costly grid upgrades and balance enterprise data-center loads with consumer needs.
Strategic rationale for ENTO
• Entry into a secular growth market: The acquisition positions ENTO squarely within the AI + energy nexus, a sector with strong tailwinds and no signs of slowing, per multiple investment-bank research outlooks on data-center power growth.
• Scalable software & services model: GRID AI's grid-edge platform targets recurring SaaS-like revenues from utilities and retailers, with potential to expand into industrial, commercial and hyperscaler demand-side solutions.
• Public-company springboard: ENTO expects that its public-market access can accelerate GRID AI's go-to-market, partnerships, and project financing alongside utilities and large energy users.
• Portfolio diversification: The acquisition broadens ENTO's strategy into critical infrastructure software, complementing existing capabilities and opening new adjacencies in energy flexibility, virtual power plants (VPPs), and transactive energy.
Transaction details
Under the terms of the agreement, ENTO acquired
To the extent required by NASDAQ's change of control rules and regulations, ENTO will file an initial listing application for its common stock.
About GRID AI
GRID AI is a grid-edge technology business providing Dynamic Load Shaping™, DER aggregation, and AI-driven orchestration to enable a future-proof, transactive grid. Its Aggregation Management Platform leverages IoT, AI/ML and edge analytics to forecast, optimize and dispatch flexible demand across millions of devices for utilities, retailers and large energy users. www.grid-ai.com
About Entero Therapeutics, Inc. (NASDAQ:ENTO)
Entero Therapeutics is a publicly listed company on Nasdaq. Entero Therapeutics is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company's programs address significant unmet needs in GI health and comprise development of Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency. Following completion of the GRID AI acquisition, ENTO intends to continue these prior operations and to operate GRID AI as a wholly owned subsidiary and pursue opportunities at the intersection of AI and energy infrastructure.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding strategic benefits of the acquisition, market opportunities, product capabilities, stockholder approval of the transaction, Nasdaq's approval of an initial listing application, if any, and future operating results. These statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially. Important factors include, among others, our business strategy; the risk that regulatory or third-party approvals are delayed or not obtained; integration challenges; market adoption; competitive dynamics; macroeconomic and energy-market conditions; and other risks detailed from time to time in ENTO's SEC filings. ENTO undertakes no obligation to update forward-looking statements.
Investor & Media Contacts:
Entero Investor Relations
investors@enterothera.com
SOURCE: Entero Therapeutics, Inc.
View the original press release on ACCESS Newswire